Baseline organ dysfunction precluding standard vandetanib / cabozantinib multikinase inhi...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-MTC-ORGAN-DYSFUNCTION |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MTC |
| Sources | SRC-ATA-THYROID-2015 SRC-NCCN-THYROID-2025 |
Red Flag Origin
| Definition | Baseline organ dysfunction precluding standard vandetanib / cabozantinib multikinase inhibitor or selpercatinib / pralsetinib RET-selective inhibitor in advanced MTC: QTc >480 ms (vandetanib + cabozantinib QT prolongation, FDA boxed warning for vandetanib), LVEF <50% (vandetanib / cabozantinib hypertension + cardiac dysfunction), CrCl <30 mL/min (TKI dose adjustment), bilirubin >3× ULN (TKI hepatic clearance), or uncontrolled hypertension. |
|---|---|
| Clinical direction | de-escalate |
| Category | organ-dysfunction |
Trigger Logic
{
"any_of": [
{
"comparator": ">",
"finding": "qtc_ms",
"threshold": 480
},
{
"comparator": "<",
"finding": "lvef_percent",
"threshold": 50
},
{
"comparator": "<",
"finding": "creatinine_clearance_ml_min",
"threshold": 30
},
{
"comparator": ">=",
"finding": "bilirubin_ratio_to_uln",
"threshold": 3
},
{
"finding": "uncontrolled_hypertension",
"value": true
}
],
"type": "lab_value"
}
Notes
Vandetanib carries FDA boxed warning for QT prolongation, sudden death, and torsades — baseline ECG mandatory; contraindicated if QTc >450 ms or bradycardia. Cabozantinib similar QT signal + GI perforation / fistula risk. Selective RET inhibitors (selpercatinib, pralsetinib) better tolerated but still carry hypertension, transaminitis, QT prolongation — selpercatinib LIBRETTO-531 vs vandetanib showed superior PFS + better safety profile, now preferred 1L. Selpercatinib hepatic dose reductions per FDA label. Uncontrolled hypertension is gating — optimize before TKI initiation.
Used By
No reverse references found in the YAML corpus.